title: Sleeping Beauty and the Story of the Bacille Calmette-Guérin Vaccine.
abstract: Mycobacterium bovis BCG is the only available vaccine for protection against tuberculosis (TB). While BCG protects children from severe disease, it has little impact on pulmonary disease in adults. A recombinant BCG vaccine BCG ΔureC::hly (strain VPM1002) is in advanced clinical trials and shows promise for improved vaccine safety but little change in efficacy in animal models. A second-generation recombinant BCG vaccine with an additional deletion of the nuoG gene (BCG ΔureC::hly ΔnuoG) shows improved efficacy in a mouse model compared to that of VPM1002. BCG was first used in humans in 1921 and, like Sleeping Beauty pricked by the spinning wheel, we have slept for 100 years, showing a reluctance to invest in clinical development or in biomanufacturing capacity for TB vaccines. The advance of recombinant BCGs should awaken us from our sleep and call us to invest in new-generation TB vaccines and to protect the biomanufacture of our current BCG vaccine.
authors: Department of Immunology and Infection, London School of Hygiene & Tropical Medicine, London, United Kingdom Helen.Fletcher@lshtm.ac.uk.
authors: Helen A
authors: 0000-0002-0435-1006
authors: HA
authors: Fletcher
mesh_terms: D000818:Animals; D001500:BCG Vaccine / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification*; D002986:Clinical Trials as Topic; D055808:Drug Discovery / Q000639:trends*; D004353:Drug Evaluation, Preclinical; D006801:Humans; D051379:Mice; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification
chemical_list: D001500:BCG Vaccine; D014614:Vaccines, Synthetic